FDA-Approved Elacestrant Is Clinically Effective at Treating Advanced or Metastatic Breast Cancer

Aditya Bardia, MD, MPH, associate professor at Massachusetts General Hospital, Harvard Medical School, spoke with The Oncology Brothers about the EMERALD study. This randomized, open-label, active-controlled, multicenter trial found that elacestrant yields better progression-free survival compared with standard of care in ER+, HER2-metastatic breast cancer patients. The results of the study prompted the recent FDA approval of elecestrant, which is the first oral selective estrogen receptor degrader.